ClinicalTrials.gg
CompletedNCT03333655Updated Aug 12, 2022

Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy

A Phase 4 interventional study of Biopsy in Neoplasms, sponsored by Hoffmann-La Roche. Completed at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-12.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to identify mechanisms associated with acquired immune escape by comparing baseline and at-progression tissue samples from participants who derive clinical benefit from CPI treatment of metastatic cancer or hematologic malignancies.

02

Conditions studied

  • Neoplasms

Keywords

  • Metastatic Cancer
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 15 is below the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Response assessment of complete response (CR), partial response (PR), or long-term stable disease (SD) for >6 months with a cancer immunotherapy treatment for cancer or hematologic either through a marketed CPI or through participation in a Roche/Genentech CPI clinical trial.
  • Availability of tissue sample.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, lactating, or intending to become pregnant during the study.
  • Participants receiving CPI treatment as part of a non-Roche/Genentech clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Other
    Checkpoint Inhibitor Therapy

    Pre-treatment (archival) and at progression biopsy for participants with a demonstrated clinical benefit on CPI therapy will be asked to participate in the study. In addition, retrospective enrollment of patients who progressed on CPI therapy after documented response and for whom an at-progression biopsy is available, is also possible.

    Procedure: Biopsy

Interventions

  • ProcedureBiopsy

    Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.

06

What researchers measure

Primary outcomes

  1. Number of Gene Alterations in at-Progression Biopsy of Patricipants with Acquired Immune Escape

    Number of Gene Alterations Will Be Evaluated Using NGS Approaches by Comparing At-Progression Biopsy with Pre-Treatment Biopsy

    Time frame: Day 1

07

Study locations

11 sites
  • UCSF Comp Canc Ctr
    San Francisco, California 94115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine; Dept of Medicine/Div of Medical Oncology
    Saint Louis, Missouri 63108, United States
  • Herbert Irving Comprehensive Cancer Center; Herbert Irving Pavillion
    New York, New York 10032, United States
  • Sarah Cannon Cancer Center
    Arrington, Tennessee 37014, United States
  • Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)
    Toulouse, 31059, France
  • Seoul National University Hospital; Department of Oncology
    Seoul, 110-744, Korea, Republic of
  • Asan Medical Center, Uni Ulsan Collegemedicine; Dept.Internal Medicine / Divisionhematology/Oncology
    Seoul, 138-736, Korea, Republic of
  • Clinica Universitaria de Navarra; Servicio de oncología
    Pamplona, Navarra 31008, Spain
  • Hospital Univ Vall d'Hebron; Servicio de Oncologia
    Barcelona, 08035, Spain
  • Barts Hospital; Institute of Cancer
    London, EC1M 6BQ, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Aug 2022, 53 months.

Of 88 phase 4 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 64. This study's 53 months is above that.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2017
First posted
Nov 7, 2017
StartActual
Feb 16, 2018
Primary completionActual
Aug 4, 2022
CompletionActual
Aug 4, 2022
Last update
Aug 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03333655
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Feb 16, 2018
Primary completion
Aug 4, 2022
Completion
Aug 4, 2022
Last update
Aug 12, 2022

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion